KBC Securities - BIOTALYS NV (BTLS) ... Morning Notes : MDXH BB, BTLS BB, NXFIL NA

Report

KBC Securities

Guy Sips ...

Kristof Samoy
Thomas Vranken

Morning Notes : MDXH BB, BTLS BB, NXFIL NA

: MDXH BB, BTLS BB, NXFIL NA

09/01/2024 1 EN

Underlyings

BIOTALYS NV

See profile

BE0974386188 Euronext Brussels Belgium

MDXHEALTH

See profile

BE0974461940 Euronext Brussels Belgium

NX FILTRATION HLDG BV

See profile

NL0015000D50 Euronext Amsterdam Netherlands

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Guy Sips

Kristof Samoy

Thomas Vranken

Other Reports on these Companies

KBC Securities

Morning Notes : EVS BB, EXM BB, HAL NA, IVA FP, XIOR BB, NXFIL NA

: EVS BB, EXM BB, HAL NA, IVA FP, XIOR BB, NXFIL NA

May 17, 2024 May 17, 2024 1 EN

GlobeNewsWire

Mdxhealth to Present at Upcoming Investor Conferences

Mdxhealth to Present at Upcoming Investor Conferences Mdxhealth to Present at Upcoming Investor Conferences IRVINE, CA, and HERSTAL, BELGIUM – May 15, 2024 () – Mdxhealth SA (Nasdaq: MDXH), a commercial-stage precision diagnostics company, today announced that Michael K. McGarrity, Chief Executive Officer, will participate in the following investor conferences in June 2024. William Blair 44th Annual Growth Stock ConferencePresentation: Wednesday, June 5, at 5:00pm ETWebcast: Jefferies Global Healthcare ConferencePresentation: Thursday, June 6, at 1:30pm ETWebcast: Live w...

May 15, 2024 May 15, 2024 1 EN

KBC Securities

mdxhealth 1Q24 update reveal strong rev growth and refinanced debt facility

mdxhealth's 1Q24 results feature a continued strong uptake in revenues to $ 19.8m (+35% y/y), supported by 16% growth in prostate test volume. The company expects the new germline test to start contributing revenue as of Q2, and on the back of strong growth prospects across the menu raises its FY24 rev guidance to $ 83-85m (prev. $ 79-81m). mdxhealth also refinanced its existing debt through a new $ 100m facility with OrbiMed, replacing the existing Innovatus loan and bringing in $ 20m new cash. We maintain our $ 6 TP and re-iterate our Buy rating.

May 2, 2024 May 2, 2024 1 EN

Wind Energy : A deep-dive into the wind sector The wind is changing, is your portfolio keeping pace?

In a new note focusing on Wind Energy, we aim to provide a broad insight into the value chain, the risks associated with it and the positioning of the companies in the sector. The current market environment presents both opportunities and challenges for wind energy companies. The sector has faced multiple headwinds in the past, such as inflation, rising interest rates and supply chain issues, which resulted in a substantial decline in the stock prices of wind companies. However, there's a lot of upside potential driven by the growth in the sector. This is mainly caused by the Net Zero Energy...

9h / 30m 9h / 30m 1 EN

Guy Sips

Guy Sips

Jensen-Group FIRST LOOK : A good start to 2024

Jensen-Group 1Q24 revenues were up y/y 11.6% to € 109.1m. The 1Q24 order intake increased y/y 34.4% to €114.9m. As a result Jensen-Group called this “a good start to 2024”. 1Q24 EBIT came in at € 11.2m (€ 11.4m in 1Q23) resulting in 10.3% 1Q24 EBIT-margin (11.7% in 1Q23). 1Q24 net result amounted to € 11.1m (€ 1.15 EPS). We maintain for the moment our Accumulate rating and € 40 Target Price as these numbers are ahead of our FY24 forecasts of 8.8% FY24E sales growth and 9.5% FY24E EBIT-margin. We will update our model after visiting this week a Jensen-Group client.

9h / 32m 9h / 32m 1 EN

Jacob Mekhael

Jacob Mekhael

Autolus 1Q24 update reiterates pipeline timelines, obe-cel data at ASCO

Autolus reported uneventful 1Q24 results, with a cash position of $758.5m (FY23: $ 239.6m), sufficient to fund the company into the first pivotal data from obe-cel (CD19 CAR-T) in autoimmune disease (we expect this to come in 2027/2028). The company reiterated pipeline timelines, with the next key event being additional analysis and longer follow up from the phase 2 (FELIX) trial of obe-cel in r/r adult ALL, expected at ASCO in June 2024, which will provide more insight into long term durability. We reiterate our $ 11 TP and BUY rating. Autolus is one of our life sciences top picks.

May 17, 2024 May 17, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Morning Notes : MDXH BB, BTLS BB, NXFIL NA

We are a financial services provider for several types of professional clients, each with distinct needs.

Morning Notes : EVS BB, EXM BB, HAL NA, IVA FP, XIOR BB, NXFIL NA

Mdxhealth to Present at Upcoming Investor Conferences

mdxhealth 1Q24 update reveal strong rev growth and refinanced debt facility

Wind Energy : A deep-dive into the wind sector The wind is changing, is your portfolio keeping pace?

Jensen-Group FIRST LOOK : A good start to 2024

Autolus 1Q24 update reiterates pipeline timelines, obe-cel data at ASCO

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe